Hepatotoxins Stocks List

Related ETFs - A few ETFs which own one or more of the above listed Hepatotoxins stocks.

Hepatotoxins Stocks Recent News

Date Stock Title
Nov 20 SNY CDC warns of an imminent spike in COVID, flu cases
Nov 20 PRFX Crude Oil Moves Lower; Williams-Sonoma Shares Gain After Q3 Results
Nov 20 GILD Gilead Sciences, Inc. (GILD) Jefferies London Healthcare Conference (Transcript)
Nov 20 SNY Here’s What Drove Sanofi’s (SNY) Earnings
Nov 20 PRFX PainReform drops on late-stage trial data for post-surgical pain management after bunionectomy
Nov 20 PRFX PainReform Announces Initial Topline Data for PRF-110 Phase 3 Clinical Trial
Nov 20 SNY Sanofi: Information concerning the total number of voting rights and shares - October 2024
Nov 18 SNY FDA Accepts SNY and REGN's Dupixent Re-Submitted sBLA for Urticaria
Nov 18 GILD Gilead’s Livdelzi shows promise in PBC clinical trial
Nov 15 SNY How analysts are reacting to RFK Jr. as Trump's HHS pick
Nov 15 GILD Gilead Unveils Long-Term Data From Seladelpar In Patients With Rare Liver Disease
Nov 15 SNY FDA reviews Sanofi and Regeneron’s Dupixent label expansion for urticaria
Nov 15 GILD Gilead’s Livdelzi (Seladelpar) Demonstrated a Sustained Efficacy and Long-Term Safety Profile in Management of Primary Biliary Cholangitis
Nov 15 SNY Analysts think Wall Street's reaction to the RFK Jr. news is 'overdone.' Sort of.
Nov 15 SNY Stocks to Watch Friday: Applied Materials, Alibaba, Domino's, Novo Nordisk
Nov 15 SNY Trump’s RFK Jr. Pick Weighs on Vaccine Makers
Nov 15 SNY Regeneron, Sanofi say resubmitted application to expand Dupixent label accepted in U.S.
Nov 15 SNY European Vaccine Makers Under Pressure After Trump Picks RFK Jr to Lead Health Department
Nov 15 SNY EMA’s CHMP recommends Sanofi’s Sarclisa approval for multiple myeloma
Nov 15 ATXI Avenue Therapeutics GAAP EPS of -$1.92 misses by $0.92
Hepatotoxins

Hepatotoxicity (from hepatic toxicity) implies chemical-driven liver damage. Drug-induced liver injury is a cause of acute and chronic liver disease.
The liver plays a central role in transforming and clearing chemicals and is susceptible to the toxicity from these agents. Certain medicinal agents, when taken in overdoses and sometimes even when introduced within therapeutic ranges, may injure the organ. Other chemical agents, such as those used in laboratories and industries, natural chemicals (e.g., microcystins) and herbal remedies can also induce hepatotoxicity. Chemicals that cause liver injury are called hepatotoxins.
More than 900 drugs have been implicated in causing liver injury (see LiverTox, external link, below) and it is the most common reason for a drug to be withdrawn from the market. Hepatotoxicity and drug-induced liver injury also account for a substantial number of compound failures, highlighting the need for toxicity prediction models (e.g. DTI), and drug screening assays, such as stem cell-derived hepatocyte-like cells, that are capable of detecting toxicity early in the drug development process. Chemicals often cause subclinical injury to the liver, which manifests only as abnormal liver enzyme tests.
Drug-induced liver injury is responsible for 5% of all hospital admissions and 50% of all acute liver failures.

Browse All Tags